FH 5.1.2Sh

General

Cell Line

hPSCreg name ICGi038-A
Cite as:
ICGi038-A (RRID:CVCL_B5EN)
Alternative name(s)
FH 5.1.2Sh
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
ICGi037-A
(FH 3.2.8T)
Donor's gene variants:
LDLR, LDLR
Donor diseases:
Hyperlipoproteinemia, Type IIa
ICGi036-A
(FH 1.3.1S)
Donor's gene variants:
LDLR, LDLR
Donor diseases:
Hyperlipoproteinemia, Type IIa
Last update 8th February 2022
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences (ICG)
Owner Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences (ICG)
Distributors
Derivation country Russia

External Databases

BioSamples SAMEA11421032
Cellosaurus CVCL_B5EN
Wikidata Q110432915

General Information

Publications
* Is the cell line readily obtainable for third parties?
Yes
Research use: allowed
Clinical use: not allowed
Commercial use: not allowed

Donor Information

General Donor Information

Sex female

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
The donor is a carrier of a disease-associated mutation and affected.
Synonyms
  • FH
  • Hyperlipidemia Type IIa
  • Type IIa Hyperlipidemia
  • Familial Hypercholesterolemia
  • Hyperlipoproteinemia, Type IIa
show more synonyms
Genetic variants
LDLR (target)
19p13.2
NM_000527.4:c.1246C>T
NP_000518.1:p.Arg416Trp
LDLR (target)
19p13.2
NM_000527.4:c.940+3_940+6delGAGT
Disease associated phenotypes
  • familial hypercholesterolemia

External Databases (Donor)

BioSamples SAMEA11421033

Ethics

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? Yes
Do you (Depositor/Provider) hold the original Donor Consent Form? Yes
Alternatives to consent are available? No
Is there other documentation provided to the donor for consenting purposes? No
Confirm that consent was obtained by a qualified professional Yes
Has the donor agreed to be re-contacted? Yes
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. pseudonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? Yes
How may genetic information associated with the cell line be accessed? Open Access
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? Federal State Budgetary Institution NATIONAL MEDICAL RESEARCH CENTER OF CARDIOLOGY Ministry of Health of the Russian Federation
Approval number 246
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?

hIPSC Derivation

General

Source cell type
A peripheral blood cell with a single nucleus. This category includes lymphocytes and monocytes.
Synonyms
  • PERIPHERAL BLOOD MONONUCLEAR CELL
  • Peripheral Blood Mononuclear Cell
  • PBMC

Reprogramming method

Vector type Non-integrating
Vector Episomal

Vector free reprogramming

Other

Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions

Feeder cells
Yes
Passage method Enzymatically
TrypLE
CO2 Concentration 5 %
Medium Other medium:
Base medium: koDMEM
Main protein source: Knock-out serum replacement
Serum concentration: 15 %
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
TRA 1-60
Yes
SSEA-4
Yes
NANOG
Yes
POU5F1 (OCT-4)
Yes
Morphology pictures
FH_5-1-2Sh morphology.tif
FH_5-1-2Sh morphology
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro spontaneous differentiation
Marker Expressed
FOXA2
Yes
KRT18
Yes
Morphology
FH_5-1-2Sh HNF3b.tif
FH_5-1-2Sh HNF3b(FOXA2)
FH_5-1-2Sh CK18.tif
FH_5-1-2Sh KRT18
Mesoderm
Ont Id: UBERON_0000926
In vitro spontaneous differentiation
Marker Expressed
ACTA2
Yes
CD90
Yes
Morphology
FH_5-1-2Sh asma.tif
FH_5-1-2Sh aSMA (ACTA2)
FH_5-1-2Sh CD90.tif
FH_5-1-2Sh CD90
Ectoderm
Ont Id: UBERON_0000924
In vitro spontaneous differentiation
Marker Expressed
TUBB3
Yes
NEFH
Unknown
Morphology
FH_5-1-2Sh TUBB3.tif
FH_5-1-2Sh TUBB3
FH_5-1-2Sh NF200.tif
FH_5-1-2Sh NF200 (NEFH)

Microbiology / Virus Screening

Mycoplasma Negative

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46,XX
Passage number: 10
Karyotyping method: G-Banding

Other Genotyping (Cell Line)